Ocular disease caused by herpes simplex virus affects up to 500,000 people in the United States. It is known that innate host resistance, host immune responses, and viral genes affect the severity of ocular disease. The continuing goal of this project has been to identify genes in HSV that are critical for the development of severe keratitis and to understand how the gene products contribute to disease severity. Several HSV genes are known to affect various components of virulence, including genes we have identified in past studies. Traditionally, approaches to such studies have focused on single genes at a time. In reality, multiple viral genes interact to promote virulence and little is known about such interactions and how they affect virulence. We have established a system with HSV whereby we can examine the contributions of multiple viral genes in the development of the virulence phenotype. Our system represents the first such system developed for a large DNA virus. Studies completed in the previous funding period have shown that there are at least six determinants involved. The US1 gene was identified as one determinant and several mutations were identified in the US1 gene. Using site directed mutagenesis, we have shown that reversion of either of two of the mutations (S34A and Y116C) restores virulence in marker transfer studies.
The Specific Aims are to: (1) Construct viruses carrying reversions of the specific mutations and use these viruses for in vitro and in vivo studies on the effect of the specific mutations on viral growth, replication cycle events, ocular and neurovirulence, and latency; (2) test the hypothesis that S34 and Y116 are phosphorylation sites in the wild type HSV US1 protein using phosphoaminoacid analysis, antibody pulldowns and co-precipitation, and mass spectroscopy methods; (3) Test the hypothesis that specifically modified isoforms of the US1 protein carry out specific functions related to virulence and correlate isoforms with functions (e.g. isoform A is involved with function B). These studies will add to our knowledge of the role of the US1 protein in ocular HSV infections and may lead to improved therapies.
|Kolb, Aaron W; Ané, Cécile; Brandt, Curtis R (2013) Using HSV-1 genome phylogenetics to track past human migrations. PLoS One 8:e76267|
|Kolb, Aaron W; Schmidt, Timothy R; Dyer, David W et al. (2011) Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant. Invest Ophthalmol Vis Sci 52:4630-8|
|Kolb, Aaron W; Adams, Marie; Cabot, Eric L et al. (2011) Multiplex sequencing of seven ocular herpes simplex virus type-1 genomes: phylogeny, sequence variability, and SNP distribution. Invest Ophthalmol Vis Sci 52:9061-73|
|Altmann, S E; Jones, J C; Schultz-Cherry, S et al. (2009) Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide. Virology 388:248-59|
|Akkarawongsa, Radeekorn; Potocky, Terra B; English, Emily P et al. (2008) Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides. Antimicrob Agents Chemother 52:2120-9|
|Cai, Suping; Brandt, Curtis R (2008) Induction of interleukin-6 in human retinal epithelial cells by an attenuated Herpes simplex virus vector requires viral replication and NFkappaB activation. Exp Eye Res 86:178-88|
|Teuton, Jeremy R; Brandt, Curtis R (2007) Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells. J Virol 81:3731-9|
|Brandt, Curtis R; Akkarawongsa, Radeekorn; Altmann, Sharon et al. (2007) Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis. Invest Ophthalmol Vis Sci 48:5118-24|
|Bultmann, Hermann; Teuton, Jeremy; Brandt, Curtis R (2007) Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain. Antimicrob Agents Chemother 51:1596-607|
|Akkarawongsa, Radeekorn; Cullinan, Amy E; Zinkel, Andrew et al. (2006) Corneal toxicity of cell-penetrating peptides that inhibit Herpes simplex virus entry. J Ocul Pharmacol Ther 22:279-89|
Showing the most recent 10 out of 42 publications